Klaria Pharma AB announced that is has started a clinical trial with Naloxone Alginate Film and that the first group of subjects have received their first doses in the trial. The data from this clinical trial will be used to submit an application for approval with both the EMA in Europe and the FDA in the United States. With a more patient friendly formulation that is being specifically developed to meet the needs of patients and caregivers, Naloxone Alginate Film has the potential to be superior to all Naloxone nasal sprays currently in use. Naloxone Alginate Film is addressing a market with significant unmet medical needs. This is especially true in the United State where in 2019 there were 168 million prescriptions written for opioids and where more than 50.000 deaths from opioid overdose occurred. Opioid overdose continues to be a significant medical and humanitarian challenge, with a steadily increasing number of deaths every year. To help address this issue, the Biden Administration has officially recommended an increase in so called co-prescription, whereby a Naloxone product will be prescribed together with an opioid.